From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides-Mechanisms and Applications
Du-Min Jo1, Fazlurrahman Khan2,3, Seul-Ki Park4
1National Marine Biodiversity of Korea (MABIK), Seochun 33662, Republic of Korea.
Marine Drugs
|October 25, 2024
Summary
Marine peptides are potent inhibitors of angiotensin-converting enzyme (ACE). Their unique properties and diverse applications offer promising therapeutic potential for cardiovascular diseases and other conditions.
Area of Science:
- Marine biotechnology
- Biochemistry
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are crucial for managing cardiovascular diseases.
- Marine bioactive peptides offer a promising alternative source for ACE inhibitors due to their structural diversity and bioactivities.
- Research is increasingly focusing on aquatic sources for novel therapeutic compounds.
Purpose of the Study:
- To review recent research on marine peptides with ACE-inhibitory activity and their applications.
- To explore the mechanisms by which marine peptides inhibit ACE.
- To assess the therapeutic potential and future research directions for marine-derived ACE inhibitors.
Main Methods:
- Literature review of studies on marine peptides and their ACE-inhibitory action.
- Analysis of mechanisms of ACE inhibition by marine peptides.
- Evaluation of extraction, application, and pharmacological properties of marine peptides.
Main Results:
- Marine peptides exhibit significant ACE-inhibitory action through various mechanisms, including competitive binding and conformational interference.
- Low IC50 values indicate high efficacy, with unique 3D structures contributing to inhibition.
- Marine peptides possess additional beneficial properties such as antioxidant, antihypertensive, and antimicrobial effects, alongside good absorption rates and low toxicity.
Conclusions:
- Marine peptides represent a valuable source of ACE inhibitors with broad therapeutic potential for cardiovascular diseases.
- Further research is needed to optimize manufacturing processes and conduct in vivo, preclinical, and clinical assessments.
- Marine peptides offer a sustainable and effective approach to developing novel treatments and addressing global health challenges.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...